In the last trading session, 2.72 million shares of the Adma Biologics Inc (NASDAQ:ADMA) were traded, and its beta was 0.62. Most recently the company’s share price was $15.81, and it changed around -$0.15 or -0.94% from the last close, which brings the market valuation of the company to $3.68B. ADMA currently trades at a discount to its 52-week high of $21.13, offering almost -33.65% off that amount. The share price’s 52-week low was $3.12, which indicates that the current value has risen by an impressive 80.27% since then. We note from Adma Biologics Inc’s average daily trading volume that its 10-day average is 3.54 million shares, with the 3-month average coming to 5.23 million.
Adma Biologics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended ADMA as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Adma Biologics Inc is expected to report earnings per share of 0.13 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adma Biologics Inc (NASDAQ:ADMA) trade information
Instantly ADMA has showed a red trend with a performance of -0.94% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 16.35 on recent trading dayincreased the stock’s daily price by 3.3%. The company’s shares are currently up 249.78% year-to-date, but still up 0.19% over the last five days. On the other hand, Adma Biologics Inc (NASDAQ:ADMA) is -18.67% down in the 30-day period. We can see from the shorts that 16.07 million shares have been sold at a short interest cover period of 2.09 day(s).
The consensus price target as assigned by Wall Street analysts is $16, which translates to bulls needing to increase their stock price by 1.19% from its current value. Analyst projections state that ADMA is forecast to be at a low of $14 and a high of $18.
Adma Biologics Inc (ADMA) estimates and forecasts
Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 1,200.00% in revenue this quarter, and will report an increase of 275.00% in the next quarter. The year-over-year growth rate is expected to be 57.10%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 105.85M in revenue for the current quarter. 4 analysts expect Adma Biologics Inc to make 110.7M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 49.80%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 38.68%.
ADMA Dividends
Adma Biologics Inc’s next quarterly earnings report is expected to be released in November.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.58% of Adma Biologics Inc shares, and 82.90% of them are in the hands of institutional investors. The stock currently has a share float of 85.10%. Adma Biologics Inc stock is held by 358.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 8.1462% of the shares, which is about 18.64 million shares worth $208.45 million.
VANGUARD GROUP INC, with 6.3426% or 14.52 million shares worth $162.3 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
